Arrowhead Pharmaceuticals (ARWR) Return on Capital Employed (2011 - 2026)
Arrowhead Pharmaceuticals (ARWR) posted Return on Capital Employed of 13.52% for Q1 2026, down 151.62% on a QoQ basis from 26.2% in Q4 2025, and down 247.0% year-over-year from 9.2% in Q1 2025.
Arrowhead Pharmaceuticals (ARWR) Return on Capital Employed (2011 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 13.52% for Q1 2026.
- Quarterly Return on Capital Employed fell 247.0% year-over-year to 13.52% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 13.52% (down 247.0% YoY) and the FY2025 annual result came in at 9.22%, up 7997.0% from the prior year.
- Return on Capital Employed was 13.52% for Q1 2026 at Arrowhead Pharmaceuticals, down from 26.2% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 26.2% in Q4 2025 and bottomed at 66.51% in Q2 2024.
- A 5-year average of 28.41% and a median of 23.49% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed sank 4656 bps — and 2025, when it surged 8988 bps.
- Arrowhead Pharmaceuticals' Return on Capital Employed stood at 23.49% in 2022, then plunged by 102 bps to 47.36% in 2023, then tumbled by 34 bps to 63.68% in 2024, then surged by 141 bps to 26.2% in 2025, then plunged by 152 bps to 13.52% in 2026.
- Business Quant data shows ARWR's Return on Capital Employed at 13.52% in Q1 2026, 26.2% in Q4 2025, and 8.28% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Arrowhead Pharmaceuticals | 11.98 Bn | 10.18 Bn | - | -13.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.52% |
| Dec 31, 2025 | 26.20% |
| Sep 30, 2025 | 8.28% |
| Jun 30, 2025 | -8.42% |
| Mar 31, 2025 | -11.05% |
| Dec 31, 2024 | -63.68% |
| Sep 30, 2024 | -66.15% |
| Jun 30, 2024 | -66.51% |
| Mar 31, 2024 | -65.30% |
| Dec 31, 2023 | -47.36% |
| Sep 30, 2023 | -30.36% |
| Jun 30, 2023 | -23.34% |
| Mar 31, 2023 | -18.74% |
| Dec 31, 2022 | -23.49% |
| Sep 30, 2022 | -30.62% |
| Jun 30, 2022 | -26.62% |
| Mar 31, 2022 | -22.27% |
| Dec 31, 2021 | -35.05% |
| Sep 30, 2021 | -25.87% |
| Jun 30, 2021 | -24.39% |